Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

Bibliographic Details
Main Authors: J.M. Piulats, E. Yu, G. Gravis, B. Laguerre, J. Arranz, S. Oudard, P. Fong, M. Kolinsky, M. Augustin, S. Feyerabend, A.. Kam, H. Gurney, A. Tafreshi, M. Retz, W. Berry, N. Mar, H. Wu, C. Schloss, C. Poehlein, J. De Bono
Format: Article
Language:English
Published: Elsevier 2020-07-01
Series:European Urology Open Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168320331645

Internet

http://www.sciencedirect.com/science/article/pii/S2666168320331645

Similar Items